Barinthus Biotherapeutics plc (BRNS) Stock

About Barinthus Biotherapeutics plc

—

the stock is valued at a negative price-to-earnings (P/E) ratio of -0.41, reflecting a net loss over the last twelve months. Over the past 52 weeks the stock has ranged between $0.51 and $2.91, and currently trades 77.0% below its 52-week high.

On profitability, Barinthus Biotherapeutics plc generates a return on equity (ROE) of -89.19% (negative, reflecting a net loss), return on capital employed of -80.68%.

Barinthus Biotherapeutics plc by the numbers, 2020–2025

Between 2020 and 2025 Barinthus Biotherapeutics plc reported revenue of $5.0M rising to $0, a change of -100.0% across 6 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-66.0M.

On a trailing twelve-month basis to Mar '26, revenue is — and net profit $-62.0M.

Cash from operations was $-48.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -38.7% over five years, and was -89.2% in the most recent year.

The share price itself has compounded at —% a year over five years, -33.3% over three, -52.8% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Barinthus Biotherapeutics plc (BRNS) — frequently asked questions